published meta-analysis   sensitivity analysis   studies

convalescent plasma treatment in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsAlQahtani, 2020 0.47 [0.04; 5.69] 0.47[0.04; 5.69]AlQahtani, 202010%40moderatenot evaluable deathsdetailed resultsAlQahtani, 2020 0.47 [0.04; 5.69] ConCOVID (Gharbharan et al.), 2020 0.95 [0.20; 4.59] ConPlas-19, 2020 0.13 [0.01; 2.54] Li, 2020 0.59 [0.22; 1.59] Libster, 2020 0.50 [0.09; 2.71] O’Donnell, 2021 0.47 [0.21; 1.06] PlasmAr, 2020 0.93 [0.47; 1.85] RECOVERY (plasma), 2021 1.00 [0.93; 1.07] 0.96[0.84; 1.10]AlQahtani, 2020, ConCOVID (Gharbharan et al.), 2020, ConPlas-19, 2020, Li, 2020, Libster, 2020, O’Donnell, 2021, PlasmAr, 2020, RECOVERY (plasma), 202182%12,582moderateserious deaths (time to event analysis only)detailed resultsPlasmAr, 2020 0.93 [0.47; 1.85] 0.93[0.47; 1.85]PlasmAr, 202010%333lownot evaluable clinical deteriorationdetailed resultsConPlas-19, 2020 0.27 [0.06; 1.25] Libster, 2020 0.52 [0.29; 0.94] 0.48[0.28; 0.83]ConPlas-19, 2020, Libster, 202020%241moderatenot evaluable clinical improvementdetailed resultsConPlas-19, 2020 0.94 [0.59; 1.50] Li, 2020 1.40 [0.79; 2.49] O’Donnell, 2021 1.20 [0.87; 1.65] PlasmAr, 2020 0.81 [0.50; 1.31] 1.08[0.87; 1.34]ConPlas-19, 2020, Li, 2020, O’Donnell, 2021, PlasmAr, 202040%740moderatenot evaluable clinical improvement (14-day)detailed resultsLi, 2020 2.27 [0.90; 5.72] 2.27[0.90; 5.72]Li, 202010%103moderatenot evaluable clinical improvement (28-day)detailed resultsLi, 2020 1.42 [0.65; 3.10] O’Donnell, 2021 1.38 [0.73; 2.61] 1.40[0.85; 2.29]Li, 2020, O’Donnell, 202120%326moderatenot evaluable clinical improvement (7-day)detailed resultsLi, 2020 0.98 [0.27; 3.58] 0.98[0.27; 3.58]Li, 202010%103moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsConPlas-19, 2020 0.94 [0.59; 1.50] Li, 2020 1.40 [0.79; 2.49] O’Donnell, 2021 1.20 [0.87; 1.65] PlasmAr, 2020 1.00 [0.76; 1.32] 1.09[0.91; 1.30]ConPlas-19, 2020, Li, 2020, O’Donnell, 2021, PlasmAr, 202040%741moderatenot evaluable death or ventilationdetailed resultsConPlas-19, 2020 0.08 [0.00; 1.53] RECOVERY (plasma), 2021 0.99 [0.93; 1.05] 0.45[0.05; 4.34]ConPlas-19, 2020, RECOVERY (plasma), 2021264%11,022moderatenot evaluable mechanical ventilationdetailed resultsAlQahtani, 2020 0.67 [0.22; 2.02] O’Donnell, 2021 1.50 [0.47; 4.82] PlasmAr, 2020 0.86 [0.39; 1.93] RECOVERY (plasma), 2021 0.98 [0.88; 1.09] 0.98[0.88; 1.08]AlQahtani, 2020, O’Donnell, 2021, PlasmAr, 2020, RECOVERY (plasma), 202140%11,537moderatenot evaluable ICU admissiondetailed resultsLibster, 2020 0.33 [0.07; 1.58] 0.33[0.07; 1.58]Libster, 202010%160lownot evaluable serious adverse eventsdetailed resultsConPlas-19, 2020 0.96 [0.29; 3.17] O’Donnell, 2021 0.64 [0.35; 1.17] PlasmAr, 2020 1.40 [0.78; 2.51] 0.95[0.55; 1.64]ConPlas-19, 2020, O’Donnell, 2021, PlasmAr, 2020340%633moderatenot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2021-05-14 02:43 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 538,957 - roots T: 290